Real-world outcomes and biomarker testing in cancer patients: exploration of a novel genetic database from routine clinical practice in England: Fiona C Ingleby, IQVIA, London, UK Saskia P Hagenaars, IQVIA, London, UK Alexandrina Lambova, IQVIA, Sofia, Bulgaria Mounika Parimi, IQVIA, London, UK Stephen Benson, IQVIA, London, UK, Sophie Jose, HDI, London, UK, Lora Frayling, HDI, London, UK Valeria Lascano, IQVIA, London, UK. Presented at Phuse EU Connect 2023 https://phuse.global/
Genetic biomarker testing offers valuable insight into cancer diagnosis, prognosis, and treatment. This study explores potential for novel real-world biomarker data linked to the English cancer registry (National Cancer Registration Dataset, NCRD) to enable biomarker-stratified analyses of routine clinical care data. Using biomarker-tested cohorts of cancer patients diagnosed between 2012 and 2019, the content, structure, and capabilities of the data were explored. Patient cohort and diagnosis identification methods were examined, and descriptive analyses of timing of biomarker tests and biomarker test results were used to explore patient distributions and characteristics. Potential for biomarker-stratified analysis of outcomes was also explored via stratified analysis of overall survival by key biomarkers of interest per each cancer type. The results highlight the need for careful methodology and data checks to ensure reliable analyses, and consideration of multiple biomarker tests per patient for appropriate stratification of analyses. Overall, the study demonstrates the crucial novel genetic real-world data provided by NCRD for identifying genetic biomarkers and aiding research to improve cancer patient outcomes in a targeted therapy setting.